MOUNTAIN VIEW, Calif.,
June 21, 2012 /PRNewswire/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the
Company will present data on LEVADEX® (formerly MAP0004), an orally
inhaled investigational drug for the acute treatment of migraine,
at the 54th Annual Scientific Meeting of the American Headache
Society (AHS) in Los Angeles, CA,
June 21-24, 2012.
The Company will present five poster presentations:
- Acute Inhalation Safety of MAP0004: Studies in Healthy
Volunteers, Smokers, and Patients With Asthma: Analysis of
three studies did not show a significant acute effect on pulmonary
function associated with the use of MAP0004.
- Sustained Pain Relief With Dihydroergotamine in Migraine Is
Potentially Due to Persistent Binding to 5-HT(1B) and
5-HT(1D) Receptors: DHE binds to 5-HT(1B) and 5-HT(1D)
receptors, which play a key role in the acute treatment of migraine
and, therefore, prolonged binding to these receptors may be a
mechanism for the sustained pain relief seen with DHE.
- Rescue Medication Use in the Acute Treatment of Migraine
During MAP0004 Pivotal Trial: This post hoc analysis shows that
rescue medication use in the MAP0004 pivotal trial was
significantly lower with MAP0004 than with placebo overall and
across most demographic and baseline characteristics.
- Analysis of the Development of Allodynia: Correlation
Between Migraine Duration and Severity: This retrospective
analysis suggests that migraine severity is a significant factor in
determining whether a subject will experience central
sensitization, as measured by allodynia.
- Mechanism of Action of Abortive Migraine-Specific
Medications: This review of the literature supports the
different mechanisms of action of the two classes of
migraine-specific drugs and suggests the nomenclature of
seroto-adrenergic modulators (SAMs) and serotonergic- specific
drugs to define these drugs based on their mechanisms of action,
rather than their chemical structure.
All poster presentations will be presented at the Hyatt Regency
Century Plaza in Los Angeles, CA
from 11:30 a.m. on Thursday, June 21 through 8:00 p.m. on Saturday,
June 23. Authors will stand by their posters to answer
questions during the following times: Friday, June 22, 12:45
p.m. – 2:00 p.m. and
Saturday, June 23, 1:00 p.m. – 2:15
p.m. All times are Pacific Time.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on
developing and commercializing new therapies to address undermet
patient needs in neurology. The Company is developing LEVADEX®, an
orally inhaled investigational drug for the acute treatment of
migraine. The U.S. Food and Drug Administration (FDA) reviewed the
New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete
Response letter with respect to this NDA. MAP Pharmaceuticals has
entered into a collaboration agreement with Allergan, Inc. to
co-promote LEVADEX to neurologists and pain specialists in the U.S.
and Canada. The Company also
applies its proprietary drug particle and inhalation technologies
to generate new pipeline opportunities by enhancing the therapeutic
benefits of proven drugs, while minimizing risk by capitalizing on
their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
CONTACT:
Lisa Borland, MAP
Pharmaceuticals, Inc., 650-386-3122
SOURCE MAP Pharmaceuticals, Inc.